Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.46 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.45 |
| ▸ | TXNRD3 | Q86VQ6 | 1/20 | 0.45 |
| ▸ | TXNRD2 | Q9NNW7 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 4/20 | 0.42 |
| ▸ | MAPT | P10636 | 4/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.41 |
| ▸ | HSPB1 | P04792 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1269012 | 0.86 | CYP1A2 (0.53) | CYP1A2TDP1ALDH1A1GPR35MAPK1 | |
| SCHEMBL5544882 | 0.83 | ALDH1A1 (0.54) | CYP1A2TDP1ALDH1A1GPR35MAPK1 | |
| SCHEMBL4943689 | 0.83 | CYP1A2 (0.60) | CYP1A2TDP1ALDH1A1GPR35MAPK1 | |
| SCHEMBL9518662 | 0.83 | POLB (0.45) | CYP1A2TDP1ALDH1A1HPGDTSHR | |
| SCHEMBL9730842 | 0.83 | ALDH1A1 (0.51) | CYP1A2TDP1ALDH1A1TSHRSMN1; SMN2 | |
| SCHEMBL95261 | 0.83 | VCAM1 (0.47) | CYP1A2TDP1ALDH1A1MAPK1HPGD | |
| SCHEMBL9732280 | 0.80 | KAT2B (0.42) | CYP1A2TDP1ALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL27800545 | 0.80 | CYP1A2 (0.57) | CYP1A2TDP1ALDH1A1GPR35MAPK1 | |
| SCHEMBL28530574 | 0.80 | CYP1A2 (0.57) | CYP1A2TDP1ALDH1A1GPR35MAPK1 | |
| SCHEMBL27961047 | 0.79 | CYP1A2 (0.68) | CYP1A2TDP1ALDH1A1GPR35MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 305 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050037407-A1 | Methods and apparatuses for electronic determination of analytes | FEBIT AG (DE) | 2005-02-17 | — | — | US | claimed |
| US-20020160427-A1 | Methods and apparatuses for electronic determination of analytes | FEBIT AG | 2002-10-31 | — | — | US | claimed |
| EP-4387954-A1 | LONG-LIVED REDOX-ACTIVE MOLECULES WITH LOW REDOX POTENTIAL | President and Fellows of Harvard College (US) | 2024-06-26 | — | — | EP | disclosed |
| US-20240165267-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | ARES CAPITAL CORPORATION, AS AGENT | 2024-05-23 | — | — | US | disclosed |
| US-11987590-B2 | Compounds that participate in cooperative binding and uses thereof | Revolution Medicines, Inc. (US) | 2024-05-21 | — | — | US | disclosed |
| US-20240136561-A1 | ELECTRICAL REGENERATION OF ELECTROLYTES | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2024-04-25 | — | — | US | disclosed |
| CN-117794585-A | Radioimmunoconjugates and checkpoint inhibitor combination therapies | 融合制药公司 | 2024-03-29 | — | — | CN | disclosed |
| CN-117603148-A | Pharmacokinetic enhancement of difunctional chelates and uses thereof | 探针技术开发及商业化中心 | 2024-02-27 | — | — | CN | disclosed |
| EP-4292156-A1 | ELECTRICAL REGENERATION OF ELECTROLYTES | President and Fellows of Harvard College (US) | 2023-12-20 | — | — | EP | disclosed |
| EP-4289950-A2 | MACROCYCLIC COMPOUNDS THAT PARTICIPATE IN COOPERATIVE BINDING AND MEDICAL USES THEREOF | Revolution Medicines, Inc. (US) | 2023-12-13 | — | — | EP | disclosed |
| CN-116964799-A | Electric regeneration of electrolytes | 哈佛大学校长及研究员协会 | 2023-10-27 | — | — | CN | disclosed |
| EP-0158467-B1 | METHOD FOR SELECTIVE METHYLATION OF ERYTHROMYCIN A DERIVATIVES | TAISHO PHARMACEUTICAL CO. LTD (JP) | 1989-07-05 | — | — | EP | disclosed |
| EP-0273599-A1 | Process for preparing 2beta-substituted-methyl-penicillin derivatives | TAIHO PHARMACEUTICAL COMPANY LIMITED (JP) | 1988-07-06 | — | — | EP | disclosed |
| EP-0272016-A1 | 2beta-substituted-methylpenicillanic acid derivatives, and salts and esters thereof | TAIHO PHARMACEUTICAL COMPANY LIMITED (JP) | 1988-06-22 | — | — | EP | disclosed |
| CN-86108176-A | Lankacidin derivatives and process for producing the same | — | 1987-10-21 | — | — | CN | disclosed |
| US-4672109-A | Method for selective methylation of erythromycin A derivatives | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 1987-06-09 | — | — | US | disclosed |
| US-4614614-A | Process for the manufacture of optically active azetidinones | CIBA-GEIGY CORPORATION (US) | 1986-09-30 | — | — | US | disclosed |
| EP-0158467-A2 | Method for selective methylation of erythromycin a derivatives | TAISHO PHARMACEUTICAL CO. LTD (JP) | 1985-10-16 | — | — | EP | disclosed |
| EP-0126709-A1 | Process for the preparation of optically active azetidinones | CIBA-GEIGY AG (CH) | 1984-11-28 | — | — | EP | disclosed |
| US-4296128-A | ANTITHROMBOSIS AGENTS | CIBA-GEIGY CORPORATION (US) | 1981-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11987590-B2 | Compounds that participate in cooperative binding and uses thereof | CEP170, PIN1, FKBP3 | CYP1A2 4064/4885TDP1 3248/4885ALDH1A1 4800/4885 |
| US-20240165267-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, ADAR, NSUN3 | CYP1A2 4850/4885TDP1 132/4885ALDH1A1 1969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.